Krystal Biotech Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
29.9%projected annual EPS growth
Analyst Coverage
8analysts covering
FY Revenue (est.)
$512.6Mnext fiscal year
FY EPS (est.)
$7.87next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results Release | 5 Nov 2026 |
| Q4 and Full Year 2026 Financial Results Release | 16 Feb 2027 |
Monitoring Framework
Key Performance Indicators
VYJUVEK Global Net Product Revenue Quarterly116.4M
VYJUVEK Gross Margin Quarterly95.0%Target: 90%-95%
Cash and Investments Balance Quarterly1BTarget: Sustained self-funding of pipeline
Watch Items
- KB803 (Ophthalmic DEB) Registrable Data ReadoutTrigger: Top-line data release expected in late 2026Action: Evaluate clinical efficacy and prepare for potential BLA filing
- KB801 (Neurotrophic Keratitis) Registrable Data ReadoutTrigger: Top-line data release expected in late 2026
- International Commercial Expansion of VYJUVEKTrigger: Launches in Germany, France, Japan, UK, and upcoming pricing in Italy/SpainAction: Monitor ex-U.S. revenue contribution and reimbursement negotiations
Research as of 2 Sep 2026